


## A Rapid, Stereospecific Synthesis of 2-Deoxy-2-fluoro-D-glucose using the Fluoride Ion

Walter A. Szarek,\* George W. Hay, and Milton M. Perlmutter

Carbohydrate Research Institute and Department of Chemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada

The reaction of  $\text{KHF}_2$  with 1,2-anhydro-3,4 : 5,6-di-*O*-isopropylidene-1-*C*-nitro-D-mannitol (**4**) provides a rapid, stereospecific route to 2-deoxy-2-fluoro-D-glucose (**2**), the  $^{18}\text{F}$ -labelled analogue of which, (**1**), is an important radiopharmaceutical of use in medical imaging.

The central importance of 2-deoxy-2- $^{18}\text{F}$ fluoro-D-glucose (**1**) is in the exploitation of positron emission tomography (p.e.t.),<sup>1</sup> for which it has been a key to the measurement of both myocardial<sup>2</sup> and regional cerebral<sup>3</sup> glucose metabolism. Although several syntheses of 2-deoxy-2-fluoro-D-glucose (**2**) have been published,<sup>4</sup> it has been that of Ido *et al.*<sup>4c</sup> which, almost exclusively, has been used, after suitable adaptation,<sup>5</sup> for the preparation of (**1**). Very recently, brief abstracts indicating the salient features of two alternative syntheses of (**1**) were published;<sup>6†</sup> their radiochemical yields did not exceed 20%. The evident, growing interest in p.e.t.,<sup>7</sup> and the pressing




(1)

need for the efficient utilization of  $^{18}\text{F}$  in the synthesis of (**1**), prompted us to report a new, rapid, stereospecific synthesis of (**2**), in which the fluoride ion is employed. This procedure could be easily adaptable for the preparation of (**1**) for medical imaging.

Compound (**3**) is obtained readily from 1-deoxy-3,4:5,6-di-*O*-isopropylidene-1-*C*-nitro-D-manno- and -gluco-hexitol by

† Subsequent to the submission of the present manuscript, another new synthesis of (**2**) was reported: M. J. Adam, *J. Chem. Soc., Chem. Commun.*, 1982, 730.



i, H<sub>2</sub>O<sub>2</sub>, NaHCO<sub>3</sub>; ii, KHF<sub>2</sub>; iii, BCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>.

the method of Funibashi *et al.*<sup>8</sup> Treatment of **(3)** with 30% hydrogen peroxide<sup>9</sup> gave an 87% yield of a mixture of 1,2-anhydro-3,4:5,6-di-*O*-isopropylidene-1-*C*-nitro-*D*-mannitol **(4)** and *D*-glucitol, from which crystalline **(4)** (m.p. 112.5–113 °C) was isolated in 72% yield.

The epoxide ring was opened by heating **(4)** with potassium hydrogen fluoride in ethane-1,2-diol at 110 °C. Within 25 min **(4)** was no longer detectable by thin-layer chromatography on silica gel G, using 1:1 (v/v) toluene–ethyl acetate (solvent A). Extraction of the reaction solution (after dilution with water) with CH<sub>2</sub>Cl<sub>2</sub> afforded **(5)**‡ in 79% yield. Compound **(5)** (*R*<sub>f</sub>

‡ The following data are consistent with the proposed structure of **(5)**. <sup>1</sup>H n.m.r.: δ 9.34 (d, 1H, <sup>3</sup>J<sub>1,2</sub> 17.5 Hz, H-1 aldehyde), 6.02 (dd, 1H, <sup>2</sup>J<sub>2,3</sub> 32.9, <sup>3</sup>J<sub>2,3</sub> 8.4 Hz, H-2); this indicates <sup>3</sup>J<sub>1,2</sub> ca. 0 Hz.

0.37, solvent A) was shown to be homogeneous by <sup>1</sup>H- and <sup>19</sup>F-nuclear magnetic resonance spectroscopy. No evidence for the formation of the *manno*-epimer of **(5)** has been obtained, despite a careful search by chromatographic methods.

The deacetalation of **(5)** was accomplished within 5 min by treatment with a dry solution of boron trichloride in CH<sub>2</sub>Cl<sub>2</sub> at room temperature. This treatment yielded **(2)** (m.p. 159–165 °C<sup>4b</sup>) in 85% yield [66% overall yield from **(4)**]. The product was further characterized by conversion<sup>4b</sup> into 1,3,4,6-tetra-*O*-acetyl-2-deoxy-2-fluoro-β-*D*-glucopyranose, the m.p., and <sup>1</sup>H n.m.r. spectrum of which were in agreement with the data of Adamson *et al.*<sup>4b</sup>

Received, 2nd June 1982; Com. 635

## References

- 1 A. P. Wolf, *Semin. Nucl. Med.*, 1981, **11**, 2; A. Alavi, M. Reivich, J. G. Greenberg, P. Hand, A. Rosenquist, W. Rintelman, D. Christman, J. S. Fowler, A. Goldman, R. R. MacGregor, and A. P. Wolf, *ibid.*, p. 24; B. M. Gallagher, J. S. Fowler, N. I. Gutterson, R. R. MacGregor, C.-N. Wan, and A. P. Wolf, *J. Nucl. Med.*, 1978, **19**, 1154, and references therein.
- 2 M. E. Phelps, E. J. Hoffman, and C. Selin, *J. Nucl. Med.*, 1978, **19**, 1311.
- 3 M. Reivich, D. E. Kuhl, A. P. Wolf, J. G. Greenberg, M. E. Phelps, T. Ido, V. R. Casella, J. S. Fowler, and E. J. Hoffman, *Circ. Res.*, 1979, **44**, 127.
- 4 (a) J. Pačák, Z. Točík, and M. Černý, *Chem. Commun.*, 1969, 77; (b) J. Adamson, A. B. Foster, L. D. Hall, R. N. Johnson, and R. H. Hesse, *Carbohydr. Res.*, 1970, **15**, 351; (c) T. Ido, C.-N. Wan, J. S. Fowler, and A. P. Wolf, *J. Org. Chem.*, 1977, **42**, 2341; (d) W. Korytnyk and S. Valentekovic-Horvat, *Tetrahedron Lett.*, 1980, **21**, 1493; (e) T. J. Tewson and K. L. Gould, *J. Nucl. Med.*, 1982, **23**, P109.
- 5 T. Ido, C.-N. Wan, V. Casella, J. S. Fowler, A. P. Wolf, M. Reivich, and D. E. Kuhl, *J. Labelled Compd. Radiopharm.*, 1978, **14**, 175; J. Barrio, N. S. MacDonald, G. D. Robinson, Jr., A. Najafi, J. S. Cook, and D. E. Kuhl, *J. Nucl. Med.*, 1981, **22**, 372; J. S. Fowler, R. R. MacGregor, A. P. Wolf, A. A. Farrell, K. I. Karlstrom, and T. J. Ruth, *J. Nucl. Med.*, 1981, **22**, 376.
- 6 S. Levy, E. Livni, and D. R. Elmaleh, *J. Nucl. Med.*, 1982, **23**, P107; C.-Y. Shiu, P. A. Salvadori, A. P. Wolf, J. S. Fowler, and R. R. MacGregor, *J. Nucl. Med.*, 1982, **23**, P108.
- 7 See, *e.g.*, M. M. Ter-Pogossian, *Semin. Nucl. Med.*, 1981, **11**, 13; G. L. Brownell, T. F. Budinger, P. C. Lauterbur, and P. L. McGeer, *Science*, 1982, **215**, 619; M. E. Raichle, *Adv. Chem. Ser.*, 1981, **197**, 419.
- 8 M. Funabashi, K. Kobayashi, and J. Yoshimura, *J. Org. Chem.*, 1979, **44**, 1618.
- 9 N. A. Sokolov, Yu. G. Chernov, and Yu. V. Glazkov, *J. Org. Chem. USSR*, 1972, **8**, 2371; H. H. Baer and C. B. Madumelu, *Can. J. Chem.*, 1978, **56**, 1177.